Form 4: Innoviva CFO Stephen Basso Reports Stock and Option Grants

Stephen Basso, CFO of Innoviva, Inc., reports the acquisition of restricted stock units and non-statutory stock options.

Summary

• On February 24, 2025, Stephen Basso, the Chief Financial Officer of Innoviva, Inc., reported the acquisition of 10,569 shares of common stock at a price of $18.08 per share.
• These shares were granted as restricted stock units (RSUs) which vest over time.
• Basso also acquired 100,831 non-statutory stock options with an exercise price of $18.08.
• These options also vest over time.
• Following these transactions, Basso directly owns 22,402 shares and 276,730 derivative securities.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to executive compensation, which is generally viewed neutrally to positively as it aligns management interests with shareholders. The vesting schedule promotes long-term commitment.

Positives

• The grant of RSUs and stock options to the CFO aligns his interests with those of the shareholders.
• The vesting schedule incentivizes long-term commitment and performance.

Future Outlook

The document does not contain specific forward-looking statements about the company's future performance, but the equity grants suggest an expectation of continued service and contribution from the CFO.

Industry Context

Equity grants are a common practice in the pharmaceutical and biotechnology industries to incentivize executives and align their interests with shareholders. The vesting schedules are typical for such grants.

Comparison to Industry Standards

• Stock option and RSU grants are standard compensation practices for executives in publicly traded companies, particularly in the biotech and pharmaceutical sectors.
• Vesting schedules of four years with a one-year cliff (25% vesting after one year) are common.
• Companies like Amgen, Gilead Sciences, and Biogen use similar equity-based compensation to incentivize their executives.

Stakeholder Impact

• Shareholders may view the equity grants positively as they align management's interests with the company's long-term success.
• Employees may see the grants as a sign of the company's commitment to its leadership.

Key Dates

Keywords

Innoviva, Stephen Basso, CFO, Form 4, Stock Options, Restricted Stock Units, INVA, Beneficial Ownership, Vesting